Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 142

1.

Spontaneous Hall effect in the Weyl semimetal candidate of all-in all-out pyrochlore iridate.

Ueda K, Kaneko R, Ishizuka H, Fujioka J, Nagaosa N, Tokura Y.

Nat Commun. 2018 Aug 2;9(1):3032. doi: 10.1038/s41467-018-05530-9.

2.

Anomalous Hall effect derived from multiple Weyl nodes in high-mobility EuTiO3 films.

Takahashi KS, Ishizuka H, Murata T, Wang QY, Tokura Y, Nagaosa N, Kawasaki M.

Sci Adv. 2018 Jul 20;4(7):eaar7880. doi: 10.1126/sciadv.aar7880. eCollection 2018 Jul.

3.

Pharmacokinetics and Safety of DS-8500a, an Antidiabetic Drug, in Japanese Subjects with Hepatic or Renal Impairment: A Single-Center, Open-Label, Single-Dose Study.

Kato M, Ishizuka H, Taguchi T, Shiosakai K, Kamiyama E, Sata M, Yoshida T.

Adv Ther. 2018 Aug;35(8):1239-1250. doi: 10.1007/s12325-018-0739-4. Epub 2018 Jul 2.

PMID:
29968010
4.

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Mirogabalin When Coadministered With Lorazepam, Zolpidem, Tramadol, or Ethanol: Results From Drug-Drug Interaction Studies in Healthy Subjects.

Jansen M, Mendell J, Currie A, Dow J, He L, Merante D, Dishy V, Ishizuka H, Zahir H.

Clin Pharmacol Drug Dev. 2018 Jun 5. doi: 10.1002/cpdd.582. [Epub ahead of print]

PMID:
29870596
5.

Single- and multiple-dose escalation study to assess pharmacokinetics, pharmacodynamics and safety of oral esaxerenone in healthy Japanese subjects.

Kato M, Furuie H, Shimizu T, Miyazaki A, Kobayashi F, Ishizuka H.

Br J Clin Pharmacol. 2018 Aug;84(8):1821-1829. doi: 10.1111/bcp.13616. Epub 2018 Jun 7.

PMID:
29688582
6.

A Randomized, Placebo-Controlled, Double-Blind Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Repeated Doses of Mirogabalin in Healthy Asian Volunteers.

Jansen M, Warrington S, Dishy V, Ohwada S, Johnson L, Brown K, Ishizuka H.

Clin Pharmacol Drug Dev. 2018 Apr 17. doi: 10.1002/cpdd.448. [Epub ahead of print]

PMID:
29663714
7.

Spin chirality induced skew scattering and anomalous Hall effect in chiral magnets.

Ishizuka H, Nagaosa N.

Sci Adv. 2018 Feb 9;4(2):eaap9962. doi: 10.1126/sciadv.aap9962. eCollection 2018 Feb.

8.

Intrapulmonary Pharmacokinetics of Laninamivir, a Neuraminidase Inhibitor, after a Single Nebulized Administration of Laninamivir Octanoate in Healthy Japanese Subjects.

Toyama K, Furuie H, Ishizuka H.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01722-17. doi: 10.1128/AAC.01722-17. Print 2018 Jan.

9.

Identification of Circulating miRNAs Differentially Regulated by Opioid Treatment.

Toyama K, Kiyosawa N, Watanabe K, Ishizuka H.

Int J Mol Sci. 2017 Sep 16;18(9). pii: E1991. doi: 10.3390/ijms18091991.

10.

Pharmacokinetics and Safety of a Single Oral Dose of Mirogabalin in Japanese Subjects With Varying Degrees of Renal Impairment.

Kato M, Tajima N, Shimizu T, Sugihara M, Furihata K, Harada K, Ishizuka H.

J Clin Pharmacol. 2018 Jan;58(1):57-63. doi: 10.1002/jcph.974. Epub 2017 Aug 23.

11.
12.

Emergent Electromagnetic Induction and Adiabatic Charge Pumping in Noncentrosymmetric Weyl Semimetals.

Ishizuka H, Hayata T, Ueda M, Nagaosa N.

Phys Rev Lett. 2016 Nov 18;117(21):216601. Epub 2016 Nov 18.

PMID:
27911529
13.

Bulk Topological Proximity Effect.

Hsieh TH, Ishizuka H, Balents L, Hughes TL.

Phys Rev Lett. 2016 Feb 26;116(8):086802. doi: 10.1103/PhysRevLett.116.086802. Epub 2016 Feb 26.

PMID:
26967436
15.
16.

Role of ATF7-TAF12 interactions in the vitamin D response hypersensitivity of osteoclast precursors in Paget's disease.

Teramachi J, Hiruma Y, Ishizuka S, Ishizuka H, Brown JP, Michou L, Cao H, Galson DL, Subler MA, Zhou H, Dempster DW, Windle JJ, Roodman GD, Kurihara N.

J Bone Miner Res. 2013 Jun;28(6):1489-500. doi: 10.1002/jbmr.1884.

17.

Dirac half-metal in a triangular ferrimagnet.

Ishizuka H, Motome Y.

Phys Rev Lett. 2012 Dec 7;109(23):237207. Epub 2012 Dec 5.

PMID:
23368260
18.

'Fibre body': the concept of fibre in eighteenth-century medicine, c.1700-40.

Ishizuka H.

Med Hist. 2012 Oct;56(4):562-84. doi: 10.1017/mdh.2012.74.

19.

Partial disorder in an Ising-spin Kondo lattice model on a triangular lattice.

Ishizuka H, Motome Y.

Phys Rev Lett. 2012 Jun 22;108(25):257205. Epub 2012 Jun 20.

PMID:
23004651
20.

Association study of genetic polymorphisms of drug transporters, SLCO1B1, SLCO1B3 and ABCC2, in African-Americans, Hispanics and Caucasians and olmesartan exposure.

Endo S, Fukahori A, Tokuhiro S, Shinagawa A, Walker J, Yoshihara K, Ishizuka H, Ieiri I, Sugiyama Y.

J Hum Genet. 2012 Aug;57(8):531-44. doi: 10.1038/jhg.2012.63. Epub 2012 Jun 14.

PMID:
22695893
21.

Extended fluorochromism of anthracene trimers with a meta-substituted triphenylamine or triphenylphosphine core.

Li Z, Ishizuka H, Sei Y, Akita M, Yoshizawa M.

Chem Asian J. 2012 Aug;7(8):1789-94. doi: 10.1002/asia.201200310. Epub 2012 Jun 11.

PMID:
22689566
22.

Intrapulmonary distribution and pharmacokinetics of laninamivir, a neuraminidase inhibitor, after a single inhaled administration of its prodrug, laninamivir octanoate, in healthy volunteers.

Ishizuka H, Toyama K, Yoshiba S, Okabe H, Furuie H.

Antimicrob Agents Chemother. 2012 Jul;56(7):3873-8. doi: 10.1128/AAC.06456-11. Epub 2012 Apr 23.

23.

Non-Kondo mechanism for resistivity minimum in spin ice conduction systems.

Udagawa M, Ishizuka H, Motome Y.

Phys Rev Lett. 2012 Feb 10;108(6):066406. Epub 2012 Feb 10.

PMID:
22401096
24.

Field test of quantum key distribution in the Tokyo QKD Network.

Sasaki M, Fujiwara M, Ishizuka H, Klaus W, Wakui K, Takeoka M, Miki S, Yamashita T, Wang Z, Tanaka A, Yoshino K, Nambu Y, Takahashi S, Tajima A, Tomita A, Domeki T, Hasegawa T, Sakai Y, Kobayashi H, Asai T, Shimizu K, Tokura T, Tsurumaru T, Matsui M, Honjo T, Tamaki K, Takesue H, Tokura Y, Dynes JF, Dixon AR, Sharpe AW, Yuan ZL, Shields AJ, Uchikoga S, Legré M, Robyr S, Trinkler P, Monat L, Page JB, Ribordy G, Poppe A, Allacher A, Maurhart O, Länger T, Peev M, Zeilinger A.

Opt Express. 2011 May 23;19(11):10387-409. doi: 10.1364/OE.19.010387.

PMID:
21643295
25.

[Primary care enlightenment to local inhabitants--cooperation of medical institution and community pharmacy in treatment of chronic hepatitis C].

Iizuka T, Eguchi Y, Akase T, Ishizuka H, Yoshiyama Y.

Yakugaku Zasshi. 2010 Dec;130(12):1633-9. Review. Japanese.

26.

Quantum melting of charge ice and non-Fermi-liquid behavior: an exact solution for the extended Falicov-Kimball model in the ice-rule limit.

Udagawa M, Ishizuka H, Motome Y.

Phys Rev Lett. 2010 Jun 4;104(22):226405. Epub 2010 Jun 3.

PMID:
20867188
27.

A case of aggressive myeloma recognized shortly after the remission following high-dose chemotherapy with autologous peripheral blood stem cell transplantation.

Ueda K, Miura K, Hatta Y, Kobayashi S, Tanaka T, Hojo A, Ishizuka H, Sawada U, Kura Y, Takeuchi J.

Int J Hematol. 2010 Oct;92(3):531-4. doi: 10.1007/s12185-010-0665-y. Epub 2010 Aug 20.

PMID:
20725814
28.

ADAM8 enhances osteoclast precursor fusion and osteoclast formation in vitro and in vivo.

Ishizuka H, García-Palacios V, Lu G, Subler MA, Zhang H, Boykin CS, Choi SJ, Zhao L, Patrene K, Galson DL, Blair HC, Hadi TM, Windle JJ, Kurihara N, Roodman GD.

J Bone Miner Res. 2011 Jan;26(1):169-81. doi: 10.1002/jbmr.199.

29.

Assessment of the effects of renal impairment on the pharmacokinetic profile of laninamivir, a novel neuraminidase inhibitor, after a single inhaled dose of its Prodrug, CS-8958.

Ishizuka H, Yoshiba S, Yoshihara K, Okabe H.

J Clin Pharmacol. 2011 Feb;51(2):243-51. doi: 10.1177/0091270010361914. Epub 2010 Mar 2.

PMID:
20197485
30.

A case of treatment-related myelodysplastic syndrome spontaneously resolved by drug discontinuance.

Nakagawa Y, Miura K, Yamazaki T, Ishizuka H, Takei K, Sawada U, Kura Y, Hatta Y, Takeuchi J.

Int J Hematol. 2010 Apr;91(3):530-3. doi: 10.1007/s12185-010-0511-2. Epub 2010 Feb 13.

PMID:
20155339
31.

[A case of complete response treated by S-1 with concurrent radiotherapy for a gefitinib-resistant non-small cell lung cancer patient].

Fujimoto H, Oyama T, Suito T, Hashimoto K, Kameyama Y, Yasuda H, Ishizuka H.

Gan To Kagaku Ryoho. 2010 Feb;37(2):295-8. Japanese.

PMID:
20154488
32.

Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers.

Ishizuka H, Yoshiba S, Okabe H, Yoshihara K.

J Clin Pharmacol. 2010 Nov;50(11):1319-29. doi: 10.1177/0091270009356297. Epub 2010 Feb 9.

PMID:
20145259
33.

Successful post-remission therapy with a combination of all-trans retinoic acid and arsenic trioxide in an elderly Japanese patient newly diagnosed with acute promyelocytic leukemia.

Kobayashi Y, Hatta Y, Ishizuka H, Hirabayashi Y, Tanaka T, Takei K, Takeuchi J.

Int J Hematol. 2010 Jan;91(1):152-3. doi: 10.1007/s12185-009-0470-7. Epub 2009 Dec 25. No abstract available.

PMID:
20033799
34.

Minimal motif peptide structure of metzincin clan zinc peptidases in micelles.

Onoda A, Suzuki T, Ishizuka H, Sugiyama R, Ariyasu S, Yamamura T.

J Pept Sci. 2009 Dec;15(12):832-41. doi: 10.1002/psc.1184.

PMID:
19830795
35.

Effect of L-asparaginase combined with vincristine and prednisolone on acute myeloblastic leukemia (M0) associated with non-Hodgkin lymphoma.

Horikoshi A, Takei K, Iriyama N, Uenogawa K, Ishizuka H, Shiraiwa H, Hosokawa Y, Sawada S, Kitoh T.

Acta Haematol. 2009;122(1):54-7. doi: 10.1159/000243725. Epub 2009 Oct 7.

PMID:
19816010
36.

Full-length sequence of mouse acupuncture-induced 1-L (aig1l) gene including its transcriptional start site.

Ohta M, Sugano A, Goto S, Yusoff S, Hirota Y, Funakoshi K, Miura K, Maeda E, Takaoka N, Sato N, Ishizuka H, Arizono N, Nishio H, Takaoka Y.

Evid Based Complement Alternat Med. 2011;2011:249280. doi: 10.1093/ecam/nep121. Epub 2011 Feb 17.

37.

Synthesis of a potent G-quadruplex-binding macrocyclic heptaoxazole.

Tera M, Iida K, Ishizuka H, Takagi M, Suganuma M, Doi T, Shin-ya K, Nagasawa K.

Chembiochem. 2009 Feb 13;10(3):431-5. doi: 10.1002/cbic.200800563.

PMID:
19140143
38.

Internal flow in polymer solution droplets deposited on a lyophobic surface during a receding process.

Kaneda M, Hyakuta K, Takao Y, Ishizuka H, Fukai J.

Langmuir. 2008 Aug 19;24(16):9102-9. doi: 10.1021/la801176y. Epub 2008 Jul 10.

PMID:
18613707
39.

Macrocyclic hexaoxazoles as sequence- and mode-selective G-quadruplex binders.

Tera M, Ishizuka H, Takagi M, Suganuma M, Shin-ya K, Nagasawa K.

Angew Chem Int Ed Engl. 2008;47(30):5557-60. doi: 10.1002/anie.200801235. No abstract available.

PMID:
18563772
40.

Removal and regeneration of aqueous divalent cations by boehmite.

Sugiyama S, Kanda Y, Ishizuka H, Sotowa K.

J Colloid Interface Sci. 2008 Apr 15;320(2):535-9. doi: 10.1016/j.jcis.2008.01.037. Epub 2008 Mar 4.

PMID:
18295777
42.

The Dugesia ryukyuensis database as a molecular resource for studying switching of the reproductive system.

Ishizuka H, Maezawa T, Kawauchi J, Nodono H, Hirao Y, Nishimura O, Nakagawa H, Sekii K, Tasaka K, Tarui H, Agata K, Hoshi M, Kobayashi K, Sakakibara Y, Matsumoto M.

Zoolog Sci. 2007 Jan;24(1):31-7.

PMID:
17409714
43.

The effects of external heating on the permeation of oxybutynin through human epidermal membrane.

Mizushima H, Inoue K, Ishizuka H.

Biol Pharm Bull. 2007 Mar;30(3):612-5.

44.

Stereoselective pharmacokinetics of oxybutynin and N-desethyloxybutynin in vitro and in vivo.

Mizushima H, Takanaka K, Abe K, Fukazawa I, Ishizuka H.

Xenobiotica. 2007 Jan;37(1):59-73.

PMID:
17178634
45.

Enlightening the fibre-woven body: William Blake and eighteenth-century fibre medicine.

Ishizuka H.

Lit Med. 2006 Spring;25(1):72-92. No abstract available.

PMID:
17040085
46.

Bronchiolar disease associated with gold compounds administration in a patient with rheumatoid arthritis.

Hiramatsu K, Ishizuka H, Yamasaki M.

Mod Rheumatol. 2005;15(2):148-52.

PMID:
17029054
47.

Treatment of high-risk peripheral T-cell lymphomas other than anaplastic large-cell lymphoma with a dose-intensified CHOP regimen followed by high-dose chemotherapy. A single institution study.

Yamazaki T, Sawada U, Kura Y, Ito T, Takeuchi J, Hatta Y, Aikawa S, Takei K, Ishizuka H, Saiki M, Uenogawa K.

Acta Haematol. 2006;116(2):90-5.

PMID:
16914902
48.

[Pharmacokinetics of S-1].

Hirata K, Horikoshi N, Tominaga K, Sohma K, Yamaguchi K, Okazaki M, Furuhata T, Sasaki K, Nakano Y, Ishizuka H, Yamada Y, Uno S, Taguchi T, Yamamitsu S, Shirasaka T.

Gan To Kagaku Ryoho. 2006 Jun;33 Suppl 1:27-35. Review. Japanese.

PMID:
16897969
49.

Population pharmacokinetic analysis of panipenem/betamipron in patients with various degrees of renal function.

Tajima N, Ishizuka H, Naganuma H.

Chemotherapy. 2006;52(5):245-53. Epub 2006 Jul 25.

PMID:
16864999
50.

Treatment effects and predictors of a 24-week course of interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C.

Tomimatsu M, Aizawa Y, Chuganji Y, Ishizuka H, Fujita Y, Aizawa R, Abe H, Matsuda T, Itou Y, Nakanishi H, Ushiyama H, Higuchi T, Fujimoto T, Endou H, Iga D, Ohta K, Kuroda H.

J Gastroenterol Hepatol. 2006 Jul;21(7):1177-83.

PMID:
16824072

Supplemental Content

Loading ...
Support Center